

**From the Chief Medical Officer
Professor Sir Michael McBride**



Department of
Health

An Roinn Sláinte

Mánnystrie O Poustie

www.health-ni.gov.uk

HSS(MD)15/2023

FOR ACTION

Chief Executives, Public Health Agency/HSC Trusts/NIAS
Deputy Secretary SPPG

GP Medical Advisers, SPPG

All General Practitioners and GP Locums (for onward
distribution to practice staff)

OOHs Medical Managers (for onward distribution to staff)

PLEASE SEE ATTACHED FULL CIRCULATION LIST

Castle Buildings
Stormont Estate
BELFAST
BT4 3SQ

Tel: 028 9052 0563

Email: Michael.McBride@health-ni.gov.uk

Our Ref: HSS(MD)15/2024

Date: 23 May 2023

Dear Colleague

**NATIONAL PATIENT SAFETY ALERT – SHORTAGE OF ORENCIA®
CLICKJECT™ (ABATACEPT) 125MG/1ML SOLUTION FOR INJECTION PRE-
FILLED PENS**

Summary of identified safety issue:

**Actions for clinicians, HSC Trust homecare leads and homecare providers
until supply issues have been resolved:**

All affected providers MUST:

1. Not start new patients on any Orencia® (abatacept) products.
2. Work with their homecare provider(s) to identify which patients will switch to Orencia® 125mg/1ml PFS, prioritising paediatric patients and those being treated for severe treatment-resistant morphea.
3. Remaining patients should be reviewed and prescribed Orencia® 250mg powder for concentrate for solution for infusion, if appropriate. Trusts should then:
 - a. Work with their homecare provider(s) to understand their capacity for support (see Additional information); and
 - b. Organise appointments for patients to receive the infusion in a hospital setting where necessary.
4. Where the above options are not considered appropriate, review patients on a case-by-case basis to consider other treatment options.

Explanation of identified safety issue

Orencia® Clickject™ (abatacept) 125mg/1ml solution for injection pre-filled pens will be out of stock from mid-June 2024 due to a manufacturing issue resulting in delays in production.

From late August, Bristol-Myers Squibb will start to build their stockholding to ensure continuity of supply moving forward. Affected patients should only be switched back to pre-filled pens once supply resilience is confirmed.

Homecare providers (Lloyds Pharmacy Clinical Homecare (LPCH), HealthNet and Polar Speed) have sufficient stock to supply existing patients until week ending 23 June 2024.

Orencia® 125mg/1ml solution for injection pre-filled syringes (PFS) remain available, however, can only support 15% of patients switching to them (see Additional information).

Orencia® 50mg and 87.5mg solution for injection PFS are not currently marketed.

Orencia® 250mg powder for concentrate for solution for infusion vials remain available and can support a full increase in demand.

Not all homecare providers have the capacity to support the administration of Orencia® intravenous infusion at home (see Additional information).

Limited quantities of unlicensed imports of Orencia® pre-filled pens and syringes can be sourced. Lead times vary. Information relating to imports is available on the [SPS Medicines Supply Tool](#) which also details any changes to resupply dates and updates to this communication.

Additional information

The switch to an alternative abatacept presentation is complex, and the management is partially influenced by the homecare provider with whom Trusts use. All patients should be counselled on the change in formulation and frequency of administration, where relevant.

1. Switching to Orencia® 125mg/1ml solution for injection PFS:

All Orencia® homecare providers can support a switch from Orencia® 125mg/1ml pre-filled pens to Orencia® 125mg/1ml PFS without any operational burden to HSC Trusts. The homecare providers will work with Bristol-Myers Squibb to provide nurse-led training for specific patients who require any additional support.

Patients will be changed back by the homecare provider to pre-filled pens from late August 2024 onwards.

2. Switching to Orencia® 250mg powder for concentrate for solution for infusion vials:

LPCH have capacity to support the administration of Orenzia® IV infusion for most patients and Trusts using LPCH should work closely with the company to understand which patients/regions can be supported.

HealthNet cannot support the administration of Orenzia® IV infusion in a patient's home. Infusions will need to be administered in a hospital setting wherever possible. Where the hospital setting is not an option, work with HealthNet to understand their capacity for supporting in urgent cases only. Where this is not possible, Trusts may contact LPCH to understand their capacity to support additional patients during this time.

Polar Speed can support the administration of Orenzia® IV infusion for all patients. Trusts using Polar Speed should work closely with the company to understand how patients/regions can be supported.

Patients can be changed back to Orenzia® 125mg/1ml pre-filled pens in a stepwise approach from late August. Patients switched to Orenzia® IV infusion should be prioritised for switching back to pre-filled pens.

Clinical Information

Orenzia® Clickject™ 125mg/1ml pre-filled pens and PFS are licensed for the treatment of rheumatoid arthritis and psoriatic arthritis in adults. Both presentations are administered as weekly subcutaneous injections. A dose of 125 mg is given regardless of weight to adults being treated for these indications.

Orenzia® 125mg/1ml PFS are licensed for treatment of polyarticular juvenile idiopathic arthritis using weight based weekly dosing.

Orenzia® 250 mg vials are licensed for the treatment of all three of these indications. It is administered as a 30-minute intravenous infusion at the doses specified in the SmPC. Following the initial administration, it is given 2 and 4 weeks after the first infusion, then every 4 weeks thereafter.

When switching patients stabilised on SC injections to IV infusion, treatment should start on the day the SC dose is due as far as possible, in line with dosing in the SmPC, and repeated 4-weekly.


References

- [SmPC: Orenzia®](#)
- [BNF: abatacept](#)

Yours sincerely



Professor Sir Michael McBride
Chief Medical Officer



Professor Cathy Harrison
Chief Pharmaceutical Officer

Circulation List

Director of Public Health/Medical Director, Public Health Agency (*for onward distribution to all relevant health protection staff*)
Assistant Director Public Health (Health Protection), Public Health Agency
Director of Nursing, Public Health Agency
Assistant Director of Pharmacy and Medicines Management, SPPG (*for onward distribution to Community Pharmacies*)
Directors of Pharmacy HSC Trusts
Director of Social Care and Children, SPPG
Family Practitioner Service Leads, SPPG (*for cascade to GP Out of Hours services*)
Medical Directors, HSC Trusts (*for onward distribution to all Consultants, Occupational Health Physicians and School Medical Leads*)
Nursing Directors, HSC Trusts (*for onward distribution to all Community Nurses, and Midwives*)
Directors of Children's Services, HSC Trusts
RQIA (*for onward transmission to all independent providers including independent hospitals*)
Joe Brogan, Assistant Director, Head of Pharmacy and Medicines Management, Strategic Planning and Performance Group (SPPG) (*for onward distribution to SPPG Pharmacy and Medicines Management Team and community pharmacists*)
Regional Medicines Information Service, Belfast HSC Trust
Regional Pharmaceutical Procurement Service, Northern HSC Trust
Professor Donna Fitzsimons, Head of School of Nursing and Midwifery QUB
Professor Neal Cook, Head of School of Nursing, University of Ulster
Heather Finlay, CEC
Donna Gallagher, Open University
Professor Paul McCarron, Head of School of Pharmacy and Pharmaceutical Sciences, UU
Professor Colin McCoy, Head of School, School of Pharmacy, QUB
Postgraduate Pharmacy Dean, NI Centre for Pharmacy Learning and Development, QUB
Michael Donaldson, Head of Dental Services, SPPG (*for distribution to all General Dental Practitioners*)
Raymond Curran, Head of Ophthalmic Services, SPPG (*for distribution to Community Optometrists*)
Trade Union Side
Clinical Advisory Team
Louise McMahan, Director of Integrated Care, SPPG

This letter is available on the Department of Health website at
<https://www.health-ni.gov.uk/topics/professional-medical-and-environmental-health-advice/hssmd-letters-and-urgent-communications>